In HER2 transgenic mice treated with OSI-774 and Herceptin, a reduction of more than 80% in tumor thymosin beta4 and ubiquitin levels at 16 hours predicted inhibited proliferation, apoptosis and tumor reduction.
In plain wordsIn mice with tumors, the body's own thymosin beta4 fell by more than 80% early after erbB drug treatment, and this fall predicted tumor response.
- Peptide
- Thymosin beta-4 (human)
- Outcome
- DecreaseTbeta4 level reduction as predictor of tumor response to erbB inhibitors
- Study
mousen: not reported in source
- Outcome group
- Tumor growth · Cancer
Measurements
- Tbeta4 level reduction
- > 80%
- 16 hours after a single dose
Source sentences
Inhibition of tumor cell proliferation and induction of apoptosis and tumor reduction were predicted by a >80% reduction in thymosin beta4 and ubiquitin levels that were detectable after 16 hours of a single drug dose before any evidence of in situ cellular activity.
1 context sentence(design, population, supporting numbers)
We have used matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) to directly analyze protein profiles in mouse mammary tumor virus/HER2 transgenic mouse frozen tumor sections after treatment with the erbB receptor inhibitors OSI-774 and Herceptin.
This result measures the body's own Thymosin beta-4 (human). Nobody was given the peptide. It is not evidence about taking it.